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ABSTRACT 
This is the advanced approach for development of pharmaceutical product with full range and specified limits of variables during procurements, 
storage and manufacturing process with a qualification, at desired level of quality within the limits of low and higher values of variables to 
ensures  the Pharmaceutical product Quality by design (QbD) of manufacturing a finished product. The Quality by Design is depicted and a 
portion of its components recognized and process parameters with quality characteristics are identified for every unit activity. Advantages, 
openings and steps engaged with Quality by Design of Pharmaceutical items are depicted. The point of the pharmaceutical advancement is to 
plan a quality item and it’s assembling procedure to reliably convey the proposed execution of the item. Quality can't be tried into items however 
quality ought to be worked in by outline. It incorporates the Quality target item profile, basic quality traits and key parts of Quality by Design. It 
likewise gives correlation between item quality by end item testing and item quality by Quality by Design. The establishment of Quality by Design 
is ICH Guidelines. It depends on the ICH Guidelines Q8 for pharmaceutical improvement, Q9 for quality hazard administration, Q10 for 
pharmaceutical quality frameworks. It moreover gives utilization of Quality by Design in pharmaceutical improvement and assembling of 
pharmaceuticals. 
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INTRODUCTION 
Origin of QbD 
Any exchange of QbD ought to be encircled with regards to 
the business and administrative atmosphere at the time that 
FDA presented the QbD idea as a major aspect of its two-year 
activity, Pharmaceutical cGMPs for the 21st Century: A Risk-
Based Approach Pharmaceutical cGMP activity (additionally 
alluded to as the Pharmaceutical cGMP Initiative or 21st 
Century Initiative) in 2002. QbD is anything but another idea 
from a pharmaceutical innovation point of view. It is, in any 
case, another idea in respect to pharmaceutical 
administrative audit and accommodation. As a methodical 
and planned way to deal with item configuration, process 
outline and control, process execution, and nonstop change, 
QbD plans quality into the assembling procedure. Thusly, 
QbD supports advancement, nonstop quality change, and 
science-and hazard based administrative procedures and 
guarantees the accessibility of top notch pharmaceuticals to 
the shopper. 
Prior to the Pharmaceutical cGMP Initiative, the 
pharmaceutical business as of now had started pushing 
toward passing on a more science-construct approach 
through its accentuation with respect to joint effort and 
hazard based control; the Pharmaceutical cGMP Initiative 
essentially hurried that procedure. At that point, as now, the 
industry all in all was completing a lot of inventive work, yet 
neither industry nor FDA were organized to support 
information sharing. By concentrating on what the 
administrative organizations needed, pharmaceutical 
organizations restricted their danger of administrative 
presentation, however they likewise constrained the 
imperative, cross-industry information sharing that 
advances enterprises and positions them for proceeded with 
development. 
Since the introduction of administrative specialists did not 
urge quality to be incorporated with the outline of the 
pharmaceutical assembling process, numerous and dull 
assessments were the methods by which quality was 
estimated and illustrated. This quality-by-examination 
technique for checking drug-item security and viability 
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offered dependable pharmaceuticals for sale to the public yet 
expected makers to tell FDA of any change to quality or to 
the present assembling process. Contingent upon the change, 
tedious and exorbitant requalification and ensuing 
administrative endorsement may be required.  
Concentrating on the control of medication item quality, the 
activity, Pharmaceutical cGMPs for the 21st Century: A Risk-
Based Approach (in this way renamed Pharmaceutical 
Quality for the 21st Century) was expected to modernize 
FDA direction of pharmaceutical quality for veterinary and 
human medications and for human organic items, for 
example, immunizations. The objectives of the activity were 
to guarantee that administrative survey, consistence, and 
examination arrangements depend on pharmaceutical 
science and to encourage the quick reception of innovative 
advances all through the pharmaceutical business. Under any 
name, the goal-oriented activity tries to show and give cases 
of improved quality.1 
Quality by Design (QbD) is an idea initially sketched out by 
quality master Joseph M. Juran in distributions, most 
strikingly Juran on Quality by Design. Outlining for quality 
and advancement is one of the three widespread procedures 
of the Juran Trilogy, in which Juran portrays what is required 
to accomplish achievements in new items, administrations, 
and processes.Juran trusted that quality could be arranged, 
and that most quality emergencies and issues identify with 
the manner by which quality was arranged.  
While Quality by Design standards have been utilized to 
propel item and process quality in industry, and especially 
the car business, they have likewise been received by the U.S. 
Nourishment and Drug Administration (FDA) for the 
revelation, advancement, and make of medications.2 
The point of pharmaceutical improvement is to plan a quality 
item and its assembling procedure to reliably convey the 
planned execution of the item. The data and information 
picked up from pharmaceutical advancement studies and 
assembling knowledge give logical comprehension to help 
the foundation of the plan space, particulars, and assembling 
controls. Data from pharmaceutical improvement studies can 
be a reason for quality hazard administration. Recognize that 
quality can't be tried into items; i.e., quality ought to be 
worked in by outline. Changes in detailing and assembling 
forms amid advancement and lifecycle administration ought 
to be viewed as chances to increase extra learning and 
further help foundation of the outline space. 
Correspondingly, incorporation of applicable information 
picked up from tests giving sudden outcomes can likewise be 
valuable. Configuration space is proposed by the candidate 
and is liable to administrative appraisal and endorsement. 
Working inside the outline space isn't considered as a 
change. Development out of the configuration space is 
thought to be a change and would regularly start an 
administrative post endorsement change process. 
In all cases, the item ought to be intended to address 
patients' issues and the planned item execution. Systems for 
item improvement change from organization to organization 
and from item to item. The approach can likewise shift and 
ought to be sketched out in the accommodation. A candidate 
may pick either an observational approach or a more 
efficient way to deal with item improvement, or a blend of 
both. A more methodical way to deal with advancement 
(additionally characterized as quality by plan) caninclude, 
for instance, consolidation of earlier learning, aftereffects of 
studies utilizing outline of tests, utilization of value hazard 
administration, and utilization of information administration 
(ICH Q10) all through the lifecycle of the item. Such a 
deliberate approach can upgrade accomplishing the coveted 
nature of the item and help the controllers to better 
comprehend an organization's procedure. Item and process 
comprehension can be refreshed mind the information 
increased over the item lifecycle.3-7 
Quality by Design 
Pharmaceutical industries are caution on item Quality, 
Safety, and Efficacy. Item quality has been expanding by 
execute logical apparatuses, for example, QbD (Quality by 
Design). Logical methodologies will give the reasonable and 
adequate information from item improvement to assembling. 
These QbD devices will limit the hazard by expanding the 
yield and quality. These days QbD approach has been 
effectively executed in like manner definition improvement. 
USFDA has discharged particular QbD direction for quick and 
broadened discharge tranquilizes items and also 
biotechnological items. Administrative specialists are 
dependably proposing the execution of ICH quality rules Q8 
to Q11.8 
As indicated by ICH Q8 rules, QbD is characterized as , " A 
precise way to deal with advancement that starts with 
predefined targets and underscores item, process 
understanding and process control, in view of sound science 
and quality hazard management."It implies that, plan and 
build up the detailing and assembling procedure to ensure 
predefined item quality. It requires an comprehension of 
how item and process factors impact item quality. It is an 
orderly procedure to assemble the quality in to last item. 
QbD requires distinguishing proof of all basic quality traits 
and process parameters and in addition deciding the level to 
which any variety can affect the nature of the last item.9 
Concepts and Background of QbD 
Quality by Design is an idea initially sketched out by Joseph 
M. Juran in different productions. He gathered that quality 
could be arranged. The idea of QbD was specify in ICH Q8 
rules, which expresses that, "To distinguish quality can’t be 
tried in items, i.e. Quality ought to be worked in to item by 
outline." In 1970, Toyota spearheaded numerous QbD ideas 
to enhance their initial autos, since that time other industry 
innovation, media transmission and aviation taken this idea 
and make QbD. In 1990, Medical gadgets started to 
demonstrate that consolidated numerous characteristics by 
plan angles. In mid-2002 FDA distributed an idea paper on 
cGMP for 21st century. These reports communicated a 
coveted that organizations construct quality, security, and 
adequacy in to their new item as right on time as could 
reasonably be expected.10-11 
Objectives of QbD: 
 The principle goals of QbD is to guarantee the quality 
items, for that item and process attributes essential to 
wanted execution must outcome from a mix of earlier 
learning and new estimation amid advancement.  
 From this learning and information process estimation 
and wanted qualities might be developed.  
 Experimental examination would be seen as positive 
execution testing of the model capacity through Design 
space.  
 Ensures mix of item and process learning picked up 
amid improvement. 
QbD activities within FDA 
In particular, the accompanying exercises are directing the 
general execution of QbD:  
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 In FDA's Office of New Drug Quality Assessment 
(ONDQA), another hazard based pharmaceutical quality 
appraisal framework (PQAS) was set up in view of the 
utilization of item and process understanding.  
 Usage of an experimental run program to enable makers 
in the pharmaceutical business to submit data for 
another medication application exhibiting utilization of 
QbD standards, item information, and process 
understanding. In 2006, Merck and Co's. Januvia turned 
into the primary item affirmed in view of such an 
application. 
 Execution of a Question-based Review (QbR) Process 
has happened in CDER's Office of Generic Drugs.  
 CDER's Office of Compliance has assumed a functioning 
part in supplementing the QbD activity by improving 
pre-endorsement inspectional procedures to assess 
business process attainability and deciding whether a 
condition of process control is kept up all through the 
lifecycle, as per the ICH Q10 lifecycle Quality System.  
 Execution of QbD for a Biologic License Application 
(BLA) is advancing.  
While QbD will give better plan expectations, there is 
likewise a solid acknowledgment that mechanical scale-up 
and comercial fabricating background gives new and 
imperative information about the procedure and the crude 
materials utilized in that. FDA knows that learning isn't static 
and works all through the assembling lifecycle.  
FDA's arrival of the Process Validation direction in January 
2011 notes the requirement for organizations to keep 
profiting from learning picked up, and constantly enhance all 
through the procedure lifecycle by making adjustments to 
guarantee main drivers of assembling issues are immediately 
rectified. This cautious and agile approach is disclosed by 
FDA to be basic to best secure the shopper (quiet).12 
Benefits of QBD 
 QbD is good business 
 Eliminate batch failures 
 Minimize deviations and costly investigations 
 Avoid regulatory compliance problems 
 Organizational learning results in advancements of 
product quality in the future. 
 QbD is good Science 
 Better development decisions 
 Empowerment of technical staff 3,5,7,13 
Opportunities 
 Efficient, agile, flexible system 
 Manufacturing with high efficiency results in reduce 
costs and decrease in product rejections and waste 
 Build scientific knowledge base for all products 
 Better interact with industry on science issues 
 Ensure consistent information 
 Incorporate risk management 14,15 
STEPS INVOLVED IN QbD PRODUCTS 
1. Development of new molecular entity 
 Preclinical study 
 Nonclinical study 
 Clinical Study 
 Scale up 
 Submission for market Approval 
2. Manufacturing 
 Design Space 
 Process Analytical Technology 
 Real time Quality Control 
3. Control Strategy 
 Risk based decision 
 Continuous Improvement 
 Product performance 
Quality by design start up plans Steps 
1. Hire an independent Quality by design expert. 
2. Organisational audit is necessary with the expert to reduce 
a gape analysis. 
3. A workshop of basic quality by design for working 
personals. 
4. Review the expert’s report and recommendation. 
5. A draft for implementation plan, timelines and estimated 
costs is necessary. 
6. Assign the resources (or contract out). 
7. Retain the independent expert as your “Project Assurance” 
advisor.14-16 
Quality by design (QbD) teaches us to understood 
product and processes behaviour 
 Identification of critical variables with their sources are 
identified, explained and optimized. 
 Variability is controlled by the process. 
 Design space reliably predict the product quality 
attributes established for materials used, process 
parameters, environmental and other conditions and 
finally optimized. 
 To gain enhanced knowledge of product performance 
over a range of material attributes, manufacturing 
process options and process parameters considering 
appropriate use of quality risk management 
principles.6,14,15 
QbD BY PHARMACEUTICALS 
 Despite the fact that the pharmaceutical business has 
center around quality, it has neglected to stay aware of 
different ventures as far as assembling proficiency and 
profitability. 
 Current situation in the Pharmaceutical Industry 
 Cost of revalidation 
 Disconnected investigation for in-process - require 
based 
 Item determinations as essential methods for control 
 Erratic Scale?up issues 
 Powerlessness to comprehend disappointments15-17 
QUALITY TARGET PRODUCT  PROFILE 
 A synopsis of the medication improvement program 
portrayed as far as naming ideas and it basically center 
around the wellbeing and viability. 
 Depiction, Clinical Pharmacology, Indications and Usage, 
Contraindications, Warnings, Precautions, Adverse 
Reactions, Drug Abuse and Dependence Over dose 
Dosage and Administration How Supplied Animal 
Pharmacology as well as Animal Toxicology Clinical 
Studies 
 A characteristic expansion of Target Product Profile for 
item quality – Quality qualities (traits) that the 
medication item ought to have to reproducibly convey 
the remedial advantage guaranteed in the name manual 
for build-up plan technique and keep the detailing 
exertion engaged and effective. It encourages 
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distinguishing proof of what's required/basic for the 
patient/buyer in the Quality Target Product Profile, (for 
example, Critical Quality Attributes, CQAs) 
 Distinguishes dangers and best ways to deal with 
oversee. 
 Utilizations devices/empowering influences in an 
upgraded form, (for example, coordination of QbD and 
bio pharmaceutics) 
 Produces and empowers information sharing. An 
iterative, learning, life-cycle process for improving basic 
leadership and the remedial results for the patient 
advantage. 
 A medication item outlined, created and made by 
Quality Target Product Profile with detail, (for example, 
disintegration/discharge acknowledgment criteria) 
steady with the coveted in vivo execution of the 
item.17,18 
CRITICAL QUALITY ATTRIBUTES 
 It is important to recognize the quality traits that are 
basic, i.e. those characterizing immaculateness, intensity 
and surrogate for Bioavailability Criticality and so on. It 
depends on the effect of value trait/parameter on the 
wellbeing, viability and quality (manufacturability) of 
theproduct. 
 Build up a connection between CPP and CQAs: 
Identification of trait or parameters that can be utilized 
as a surrogate for clinical security and adequacy 
(essential to quiet) . 
 Manufacturability is additionally a trait (imperative to 
business) that is basic to quality. 
 The level of criticality may vary for an API fabricating 
process with respect to a medication item producing 
process 
 Programming interface is one segment of a medication 
item and above and beyond far from the patient 
continuum of Criticality. A few levels of criticality might 
be utilized to depict numerous levels of hazard. 
As property or parameter limits approach edges of 
disappointment, the level of fundamentally expanded with 
the hazard19-21 
 
Figure 1: Decision Tree to Decide CQAs 
 
Certain Key Aspects of QBD 
 Target Product Quality Profile (TPQP) is used for setting 
the key area for tranquilize advancement — "arranging 
in optimized form an extended utilization of the TPP 
being developed arranging, clinical and business basic 
leadership, administrative office communications, and 
hazard administration has begun to advance.  
 Drug Substance and Excipient Properties To reliably 
accomplish the medication item quality indicated in the 
name, the medication substance should be completely 
portrayed concerning its physical, synthetic, organic, 
and mechanical properties, for example, solvency, 
polymorphism, steadiness, molecule size, and stream 
properties. 
 Formulation Design and Development Not all model 
plans can be assessed in human subjects, which imply 
that creating touchy in vitro disintegration techniques is 
significant to a viable advancement program.22-24 
Quality target product profile for the ANDA product 
The Quality Target Product Profile (QTPP) is "an imminent 
outline of the quality attributes of a medication item that in a 
perfect world will be accomplished to guarantee the coveted 
quality, considering security and adequacy ofthe sedate 
item." Before building up the item, the quality qualities of the 
item are distinguished. In light of the coveted attributes the 
outline space is used to assess variable of value target item 
profile from which the basic quality properties as 
determined. The information got from assessment will fill in 
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as a hotspot for chance evaluation. The finding of hazard 
appraisal is analyzed and advanced process is created to 
deliver the results of wanted quality. 
 
ICH Q8 Q8, Q9, Q10 Guidelines: the foundation of 
QbD 
ICH Guidelines Q8 for Pharmaceutical Development, Q9 for 
Quality Risk Management, Q10 for Quality frameworks are 
establishment of QbD(Figure)4,513,25 
 
 
 Figure 2: The Foundation of QbD 
 
ICH Guidelines for stability study 
 Q1A (R2)- Stability testing of new drug substance and 
product. 
 Q1B-Stabilityn testing : photostability testing of new 
drug substances and products. 
 Q1C-Stability testing for new dosage forms. 
 Q1D-Bracketing and matrix designs for stability testing 
of new drug substances and products. 
 Q1E-Evaluation of stability deata. 
 Q1F-Stability data package for registration application in 
climatic zones 3 and 4. 
Quality by Design relative to ICH 
 Concepts aligned 
 Design Space - Key to understanding 
 Process robustness 
 Design of Experiments (DOE) 
 Quality management Quality management27-28 
Critical Concept: Design Space 
 Multidimensional blend with associations 
Multidimensional cooperations put factors (e.g. crude 
material properties) and process parameters  
 Demonstrated to give confirmation of value  
 Defined by candidate and assessed by controller 
Characterized controller  
 Once configuration space is endorsed, administrative 
post endorsement change prerequisites will be 
improved endorsement Inside versus outside outline 
space Inside space  
 Regulatory adaptability to work inside the plan space 
Regulatory space26,28 
BENEFITS OF IMPLEMENTING QbD FOR FDA29-36 
 Enhances scientific foundation for review 
 Provides for better coordination across 
review,compliance and inspection 
 Improves information in regulatory submissions 
 Provides for better consistency 
 Improves quality of review (establishing a QMS forCMC) 
 Provides for more flexibility in decision making 
 Ensures decisions made on science and not on empirical 
information 
 Involves various disciplines in decision making 
 Uses resources to address higher risks 
Benefits to Industry 
 Ensures better design of products with less problems in 
manufacturing 
 Reduces number of manufacturing supplements 
required for post market changes –rely on process and 
risk     understanding and risk mitigation 
 Allows for implementation of new technology to 
improve manufacturing without regulatory scrutiny 
 Allows for possible reduction in overall costs of 
manufacturing –less waste 
  Ensures less hassle during review –reduced deficiencies 
–quicker approvals 
 Improves interaction with FDA –deal on a science level 
instead of on a process level 
 Allows for continuous improvements in products and 
manufacturing process. 
Pharmaceutical Development 
Widely used in pharmaceutical development and 
manufacturing (Figure). 
 
 
Figure 3: pharmaceutical developments 
Used in PAT 
A framework for outlining, investigating and controlling  
producing through auspicious estimation of basic quality 
execution traits of crude and in process materials and 
procedures with the objective of guaranteeing last item 
quality (Figure ). 
Desired state 
pharmaceutical 
devlopment(Q8) 
Quality Risk 
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Systems(Q10) 
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Manufacturing 
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Design space 
& Control 
strategy 
Information 
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Figure 4: Off-line & On-line Analysis 
Design Space: The multidimensional blend and association 
of information factors (e.g.,material properties) and 
process parameters that have been exhibited to give 
confirmation of value. Working inside the plan space isn't 
considered as a change. Development out of the outline 
space is thought to be a change and would typically start an 
administrative postapproval change process. Configuration 
space is proposed by the candidate and is liable to 
administrative evaluation and endorsement.  
For the scientist, Quality Attributes in Design Space is Y = F 
(Process Parameters, Material Attributes) — a function or a 
relationship between process parameters and (critical) 
quality attributes /material attributes. 
 
 
Figure 5; Configuration Space 
When discussing Design Space in QbD, our other words 
come up often: Set Point, Operating Range, Accepted Range 
and Characterization Range. 
 
 
Configuration Space 
The relationship between the procedure inputs (material 
properties and process parameters) and the critical quality 
attributes can be depicted in the outline space . 
1. Determination of Variables  
The risk assessment and  process development 
experiments described in Section 2.3 can lead to a 
comprehension of the linkage and impact of process 
parameters and material properties on product CQAs and 
additionally help distinguish the factors and their goes 
inside which consistent quality can be accomplished. These 
procedure parameters and material qualities would thus be 
able to be selected for consideration in the outline space. A 
portrayal ought to be given in the use of the procedure 
parameters and material attributes considered for the plan 
space, those that were incorporated, and their impact on 
product quality. The method of reasoning for incorporation 
in the outline space ought to be displayed. In a few cases, it 
is helpful to give likewise the justification about why a few 
parameters were rejected. Knowledge gained from studies 
ought to be portrayed in the accommodation.  Process 
parameters and material attributes that were not shifted 
through advancement ought to be featured.  
2. Portraying a Design Space in a Submission  
A plan space can be portrayed as far as scopes of material 
traits and process parameters, or through more perplexing 
scientific connections. It is conceivable to depict an outline 
space as a time subordinate capacity (e.g., temperature and 
weight cycle of a lyophilization cycle), or as a combination 
of factors, for example, segments of a multivariate model. 
Scaling variables can also be included if the outline space is 
proposed to traverse different operational scales. 
Examination of historical information can add to the 
DO2 PH 
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foundation of a plan space. Notwithstanding how a 
design space is created, it is normal that task inside the 
outline space will result in a product meeting the 
characterized quality. Examples of various potential ways 
to deal with introduction of an outline space are exhibited 
in Appendix 2. 
3. Unit Operation Design Space(s)   
The candidate can build up free plan spaces for at least one 
unit operations, or to set up a solitary plan space that 
traverses different activities. While a isolate plan space for 
every unit activity is frequently less complex to build up, an 
outline space that traverses the whole process can give 
more operational adaptability. For case, on account of a 
medication item that undergoes corruption in arrangement 
previously lyophilization, the plan space to control the 
degree of degradation (e.g., fixation, time, and temperature) 
could be communicated for every unit task or as an entirety 
over all unit activities.  
4. Relationship of Design Space to Equipment Scale 
While portraying a plan space, the candidate ought to think 
about the sort of operational flexibility desired. An outline 
space can be created at any scale. The candidate ought to 
legitimize the relevance of an outline space created at little 
or pilot scale to the proposed creation scale manufacturing 
process and discuss the potential dangers in the scale-up 
operation. If the candidate proposes the plan space to be 
relevant to numerous operational scales, the design space 
ought to be depicted as far as applicable scale-free 
parameters. For example, if an item was resolved to be 
shear touchy in a blending activity, the design space could 
incorporate shear rate, as opposed to tumult rate. 
Dimensionless numbers as well as models for scaling can 
be incorporated as some portion of the outline space 
portrayal.  
5. Configuration Space versus Proven Acceptable 
Ranges  
A mix of demonstrated adequate reaches does not 
constitute an outline space. However, proven acceptable 
reaches in light of univariate experimentation can give 
helpful information about the process.  
6. Configuration Space and Edge of Failure  
It very well may be useful to decide the edge of 
disappointment for process parameters or material 
attributes, beyond which the significant quality properties 
can't be met. However, determining the edge of failure or 
exhibiting disappointment modes are most certainly not 
basic parts of setting up an outline space. Step by step 
instructions to Implement QbD Fundamentally, QbD is 
effectively interfacing the 3 center components —  
1. Hazard Assessment  
2. Configuration Space  
3. Control Strategy — keeping in mind the end goal to 
comprehend the connection of QTPP – CQA – CPP and 
control them.  
Hazard Assessment is the device to decide the connection 
of QTPP – CQA – CPP. This is the initial step and along these 
lines a basic one.  
DOE – Design of Experiments is the basic way to deal with 
portrays Design Space. 
Multidimensional blend of and collaboration of information 
factors and process parameters that have been exhibited to 
give Quality Assurance (Figure)  
 
Figure 6:  Design space 
 Linkage between process (inputs factors and process 
parameters) and    basic quality properties  
 Proposed by Applicant  
 Subject to administrative evaluation and endorsement  
 Implementation previously or after MA  
 Established for at least one unit operation(s) or up to 
finish process  
 Working inside the outline space: not considered as a 
change37 
HPV vaccine manufacturing process by using QbD 
Assembling procedure of HPV immunization can be 
performed by utilizing QbD (Figure).29-36
 
Figure 7: Manufacturing Process of HPV vaccine 
Quality by design approach in coating process 
Quality can't be tried into item yet it ought to be worked in 
item. Parameters that influence the covering process are 
given underneath. Customary and Quality by Design 
approach can be clarified for the covering process (Figure).
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Figure 8: Parameters that affects coating process 
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Figure 9: Traditional and Quality by Design approach in coating process 
 
CONCLUSION 
Exertion is to build up a dependable strategy that can be 
exhibited with a high level of affirmation to reliably deliver 
information meeting predefined criteria at the point when 
worked inside characterized limits. QbD can be connected to 
the advancement and assessment of logical strategies. Amid 
strategy improvement, every single potential factor (the 
information sources) and all basic diagnostic reactions (the 
yields) are concentrated to decide the connections. Basic 
expository elements are recognized in an approach that 
parallels what is portrayed for process advancement in ICH 
Q8 and Q9. The QbD procedure on a functioning organization 
of diagnostic researchers at both the advancement and 
operational research centers as strategies are produced and 
as factors that prompt potential strategy disappointments 
are distinguished and controlled. A corporate information 
vault is required all through the procedure to guarantee 
basic data is caught that can be audited and added to later on 
to such an extent that exercises scholarly can be connected 
to the particular strategy under thought and additionally to 
other comparative techniques being connected to other 
items. Such a storehouse (in accordance with ideas 
portrayed in the draft ICH Q10) will empower ceaseless 
change and change control of the strategy to take put all 
through its lifecycle. As opposed to proceeding to perform 
scientific innovation exchange activities and ICH approval, a 
QbD approachbased on a hazard evaluated change control 
methodology ought to be embraced. Each time a technique is 
changed, a hazard appraisal ought to be performed. Where 
the change is recognized as having the capacity to take the 
technique outside its known outline space, a strategy 
assessment and, on the off chance that suitable, an 
equivalency exercise ought to be performed to guarantee 
technique execution criteria are still met. This will take into 
account technique changes to be made by means of inside 
change control methodology, and even switches between 
various strategies (e.g., HPLC versus NIR) may turn out to be 
significantly less demanding to execute. A QbD approach for 
systematic strategies that incorporates hazard appraisal, 
vigor testing, and roughness testing is significantly more 
thorough than ICH approval prerequisites (Q2(R1)). It 
likewise incorporates an evaluation of strategy  inconstancy 
contrasted and as far as possible, which is a standout 
amongst the most imperative strategy credits to test when 
choosing whether the technique is fit for its motivation. The 
approach depicted in this recommends ICH Q2(R1), while 
including some esteem, must be generously changed to 
assess the QbD chance based methodologies depicted in this 
article. This new QbD process offers the open door for much 
more noteworthy administrative adaptability later on. The 
data derived from trial & 
error experimentation 
decision based 
casual links product 
performance 
 
Equipment variable design Formulation attributes Process parameter 
 Equipments 
Types/Dimensions 
 Nozzle  
Number /Types/ Location/ Design  
 Partition 
Diameter/Length/ presence/ 
Length of partition gap 
 Air distribution plate 
Types  
 
 Coating liquid 
Viscosity and surface tension 
Types of solvent 
Concentration of polymer 
Presence of other additives 
 Core particles 
Shape 
Size 
Density  
Humidity 
 API 
Solubility in the coating liquid 
Interaction with other excipient 
 Inlet air temperature 
 Fluidization air flow rate 
 Inlet air tempreture 
 Outlet air tempreture 
 Humidity of the inlet air 
 Humidity of the outlet air 
 
 
 Curing 
Time 
Temperature 
Humidity 
 
 
 
 
 
Monitor  Control Understand Design Identify 
Malik et al                                                                                                               Journal of Drug Delivery & Therapeutics. 2019; 9(1-s):416-424 
ISSN: 2250-1177                                                                                  [424]                                                                                 CODEN (USA): JDDTAO 
strategy execution criteria could conceivably be enlisted 
rather than the strategy itself. The strategy utilized could be 
alluded to for instance of how to achieve the required 
technique execution criteria. Any progressions to this 
strategy would be secured by inner change control 
methodology. 
REFERENCES 
1. https://www.fda.gov/downloads/drugs/developmentapproval
process/manufacturing/questionsandanswersoncurrentgood
manufacturingpracticescgmpfordrugs/ucm176374.pdf 
2. https://en.wikipedia.org/wiki/Quality_by_Design 
3. Woodcock J, The concept of pharmaceutical quality. American 
Pharmaceutical Review, 7(6), 2004, 10–15. 
4. Q9: Quality Risk Management. ICH Harmonized Tripartite 
Guidelines. International Conference on Harmonization of 
Technical Requirements for Registration of Pharmaceuticals 
for Human Use, 2006. 
5. Q10: Pharmaceutical Quality System, ICH Tripartite Guidelines. 
International Conference on Harmonization of Technical 
Requirements for Registration of Pharmaceuticals for Human 
Use, 2007. 
6. Lionberger RA, Lee LS, Lee L, Raw A ,Yu LX, Quality by design: 
Concepts for ANDAs, The AAPS, 2008; 10:268–276. 
7. FDA Guidance for Industry and Review Staff: Target Product 
Profile – A Strategic Development Process Tool (Draft 
Guidance). 
8. Lawrence X. Yu (2006) Director of science. “Implementation of 
Quality by        Design”, Question    based review. 
9. Anat IB (2013) QbD Strategy Leader, “Bud implementation in 
Generic Industry: Overview and Case-Study” IFPAC JAN. 
10. Avellant J (2008) “Why Quality by Design?” Expert Brefings pp. 
1-12. 
11. Roy S, “Quality by Design-Holistic concept of concept of 
building quality in pharmaceuticals”. Int J Pham Biomed Res 
2012; 3:100-108. 
12. https://learnaboutgmp.com/good-validation-
practices/pharmaceutical-quality-by-design-qbd-an-
introduction-process-devlopment-and-applications/ 
13. Q8 (R1): Pharmaceutical Development, Revision 1, ICH 
Harmonized Tripartite Guidelines, International Conference on 
Harmonization of Technical Requirements for Registration of 
Pharmaceuticals for Human Use, 2007. 
14. Callis JB, Illman DL, Kowalski BR, Process analytical chemistry. 
Analytical Chemistry, 1987; 59:624A–637A. 
15. Yu LX, Pharmaceutical quality by design: Product and process 
development, understanding, and control. Pharmaceutical 
Research, 2008; 25:781–791. 
16. Munson J, Gujral B, Stanfield CF, A review of process analytical 
technology (PAT) in the U.S. pharmaceutical industry. Current 
Pharmaceutical Analysis, 2006; 2:405–414. 
17. Leuenberger H, Puchkov M, Krausbauer E, Betz G, 
Manufacturing pharmaceutical granules, Is the granulation 
end-point a myth, Powder Technology, 2009; 189:141–148. 
18. Miller CE, Chemometrics and NIR: A match made in heaven, 
Am. Pharm. Rev. Food and Drug Administration CDER, 
Guidance for industry, Q8 pharmaceutical development; 2:41–
48, 2006. 
19. Nasr M. Risk-based CMC review paradigm, Advisory committee 
for pharmaceutical science meeting, 2004. 
20. Food and Drug Administration CDER. Guidance for industry: 
Immediate release solid oral dosage forms scale-up and post 
approval changes: Chemistry, manufacturing, and controls, in 
vitro dissolution testing, and in vivo bioequivalence 
documentation, 1995. 
21. Food and Drug Administration CDER. Guidance for industry: 
Modified release solid oral dosage forms scale-up and post 
approval changes: Chemistry, manufacturing, and controls, in 
vitro dissolution testing, and in vivo bioequivalence 
documentation, 1997. 
22. Food and Drug Administration CDER. Guidance for industry: 
Non sterile semisolid dosage forms scale-up and post approval 
changes: chemistry, manufacturing, and controls, in vitro 
dissolution testing, and in vivo bioequivalence documentation, 
1997. 
23. Food and Drug Administration CDER. Guidance for industry: 
Changes to an approved NDA or ANDA, 2004. 
24. Woodcock J, The concept of pharmaceutical quality. American 
Pharmaceutical Review, 2004, 1–3. 
25. Food and Drug Administration, Office of Generic Drugs White 
Paper on Question-based Review: http://www.fda.gov/cder/ 
OGD/QbR.htm. 
26. Food and Drug Administration, Guidance for industry, Q6A 
specifications for new drug substances and products: Chemical 
substances, 1999. 
27. Nasr M, FDA’s quality initiatives: An update, 
http://www.gmpcompliance. 
com/daten/download/FDAs_Quality_Initiative.pdf, 2007. 
28. IBM Business Consulting Services, Transforming 
industrialization: A new paradigm for pharmaceutical 
development, www-935.ibm.com/services/us/imc/pdf/ge 
510– 3997-transforming-industrialization.pdf, 2006. 
29. Food and Drug Administration: 
http://www.fda.gov/ohrms/dockets/ac/06/minutes/2006–
4228m1.pdf, 2006. 
30. Zhang H, Lawrence X, Dissolution testing for solid oral drug 
products: Theoretical considerations, American 
Pharmaceutical Review, 2004, 26–31. 
31. Radeke CA, Glasser BJ, Khinast, JG, Large-scale powder mixer 
simulations using massively parallel GPU architectures, 
Chemical Engineering Science, 2010; 65:6435–6442. 
32. Radl S, Kalvoda E, Glasse BJ, Khinast JG, Mixing characteristics 
of wet granular matter in a bladed mixer, Powder Technology, 
2009; 200:171–189. 
33. Rathore AS, Roadmap for implementation of Quality by Design 
(QbD) for biotechnology products, Trends in Biotechnology, 
2005; 27:546–553. 
34. Rathore AS, Brenning RCD, Cecchini D, Design space for biotech 
products. Biopharm International, 20, 36–40. 
35. Rathore AS, Winkle H, Quality by Design for 
biopharmaceuticals. Nature Biotechnology, 2009; 27:26–34. 
36. Remy B, Glasser BJ, Khinast JG, The effect of mixer properties 
and fill level on granular flow in a bladed mixer. AIChE Journal, 
2010; 56:336–353. 
37. https://qbdworks.com/design-space-in-qbd/ 
 
 
